Aspire Biopharma Holdings, Inc. (ASBP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. on April 18, 2025. The Company, formerly known as PowerUp Acquisition Corp., is incorporated in Delaware and lists its common stock (ASBP) and warrants (ASBPW) on The Nasdaq Stock Market LLC. The report addresses compliance deficiencies received from Nasdaq on April 16, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on listing compliance issues rather than financial performance data.
Material Changes and Listing Deficiencies
The Company received two deficiency notices from Nasdaq regarding the following rules:
- Market Value of Listed Securities (MVLS): The Company failed to maintain the required minimum MVLS of $50,000,000 for 30 consecutive business days (Rule 5450(b)(2)(A)).
- Minimum Bid Price: The Company failed to maintain a minimum bid price of $1.00 per share (Rule 5450(a)(1)).
Under Nasdaq Listing Rule 5810(c)(3)(C), the Company has a 180-day compliance period ending on October 13, 2025. To regain compliance, the Company must achieve and maintain an MVLS of at least $50,000,000 for a minimum of 10 consecutive business days.
Outlook, Risks, and Management Commentary
Management stated that the Company is considering actions to regain compliance but has not made any decisions at this time. There is no assurance that the Company will be able to meet the minimum bid price requirement or other listing criteria. If the Company fails to regain compliance by the October 13, 2025 deadline, its securities will be subject to delisting. At that point, the Company may appeal the determination or apply to transfer its listing to The Nasdaq Capital Market, subject to meeting those specific requirements.
Investor Verification Checklist
- Verify the current market capitalization and whether it has reached the $50,000,000 threshold required for compliance.
- Monitor the daily closing bid price to ensure it remains above $1.00 per share.
- Review subsequent filings for any announced corporate actions (e.g., reverse stock splits) intended to address the deficiencies.
- Check for any updates regarding the potential transfer to The Nasdaq Capital Market if the Global Market requirements are not met.